Bernhard Wimmer

BioM AG is a regional technology transfer and venture capital services company created in 1997 following Munich's selection in the Government-sponsored BioRegio Competition. The firm provides business support services to Munich-based biotechnology companies, focusing on startups. Through BioM Biotech Cluster Development GmbH, established in 2006, BioM coordinates the Munich Biotech Cluster, with the objective of turning it into a leading biotechnology center in Europe. They seek to foster an active cooperation between Bavarian research institutions and corporations. BioM actively invests seed capital in biotechnology startups in the Munich area, and manages a venture capital investment fund invested in high-growth early-stage businesses.

Part of Evotec SE, Evotec (München) GmbH is a German company that provides manufacturing and research support services for pharmaceutical and biotechnology companies. The company is based in Neuried, Germany. The CEOs are Dirk Ullmann, Loëtitia Edith Rouxel. The company was founded in 2005 by Axel Ullrich, Hellmut Kirchner, Henrik Daub. Evotec (München was acquired by Evotec SE on April 19, 2011 for $20.40 million.

BioM AG Munich BioTech Development (BMBD) is a venture capital firm specialized in the life sciences sector. Located in Martinsried on the outskirts of Munich, BMBD was established in 2002 to manage the investment portfolio of BioM AG, a regional technology transfer and venture capital services company. BioM was created in 1997 following Munich's selection in the Government-sponsored BioRegio Competition, and provides business support services to Munich-based biotechnology companies, focusing on start-ups. BMBD manages the BioM Venture Capital fund. Their clients include regional banks, German and European private equity firms and private individuals. The firm operates in partnership with public entities, in particular the German Federal Ministry of Education and Research (BMBF) and HighTech Gründerfonds (HTGF), a partnership between the Government of Germany, the KfW banking group and leading technology corporations.

conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany.